Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06561399
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-13
Brief Title:
Triple Therapy Sequential Radiotherapy in Unresectable HCC TALENP003
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-arm Phase II Prospective Study of Transcatheter Arterial Chemoembolization Lenvatinib Combination With Sintilimab Sequential Radiotherapy in Patients With Initial Unresectable Hepatocellular Carcinoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an Open-label Multicenter Phase II clinical trial to evaluate the efficacy and safety of Transcatheter arterial chemoembolization TACE Lenvatinib combination with Sintilimab Triple Therapy sequential radiotherapy in patients with Unresectable Hepatocellular Carcinoma uHCC
Detailed Description:
For Unresectable Hepatocellular Carcinoma uHCC patients Transcatheter arterial chemoembolization TACE Lenvatinib combined with PD-1 inhibitors treatment is an important choice which can achieve deeper tumor remission However there are still some patients whose lesions have not reached complete response after treatment According to research patients with complete response of lesions after conversion therapy have a more ideal long-term survival rate For populations that have not yet achieved complete response sequential radiotherapy will achieve deeper tumor remission delay recurrence and achieve better oncological outcomes This study is a single arm multicenter prospective clinical trial designed to evaluate the efficacy and safety of TACE Lenvatinib combination with Sintilimab Triple Therapy sequential radiotherapy in the treatment of uHCC patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None